Last updated on November 2018

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients Not on Dialysis in Comparison to Darbepoetin Alfa

Brief description of study

This study is conducted to explore a new therapy for anemia in patients with chronic kidney disease. Anemia is a reduced number of red blood cells or hemoglobin. Hemoglobin (which contains iron) is important for the transport of oxygen in your blood. The purpose of the study is to see if Roxadustat is effective and safe to treat anemia in patients with chronic kidney disease. Roxadustat will in this study be compared to darbepoetin alfa, a commercially available medicine for treatment of anemia (tradename Aranesp).

Detailed Study Description

This study will consist of three study periods as follows: - Screening Period: from 2 up to 6 weeks - Treatment Period: 104 weeks - Follow-up Period: 4 weeks

Clinical Study Identifier: NCT02021318

Contact Investigators or Research Sites near you

Start Over

Development Operations Clinical Science

Site DK45009
Hilleroed, Denmark